Trajectum Pharma B.V.

Over Trajectum Pharma B.V.

More specifically, Trajectum Pharma is developing novel mRNA-based products, formulated as lipid nanoparticles for the field of rheumatoid arthritis and other inflammatory diseases. Trajectum Pharma is developing a potentially curative, first in class treatment, for which initial proof-of-concept for the treatment of RA has been established.The initial results in preclinical disease models are extremely promising. The long-term vision of the company is to develop an off-the-shelf vaccine for RA, using the principle of tolerance induction. The company has strong ties with Utrecht University, Department of Immunology and Infectious Diseases, Faculty of Veterinary Medicine (Prof. Femke Broere). There is an ongoing co-operation in the field of mRNA technology and lipid nanoparticle formulations with the Weissman Lab at UPenn (Philadephia, PA) (Prof. Drew Weissman).

Adres

• Hoofdkantoor

  Padualaan 83584CH UtrechtUtrecht, Nederland